These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 34768962)

  • 1. Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response.
    Mendes-Pinheiro B; Soares-Cunha C; Marote A; Loureiro-Campos E; Campos J; Barata-Antunes S; Monteiro-Fernandes D; Santos D; Duarte-Silva S; Pinto L; José Salgado A
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
    Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR
    Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys.
    Eslamboli A; Baker HF; Ridley RM; Annett LE
    Exp Neurol; 2003 Oct; 183(2):418-29. PubMed ID: 14552882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat.
    Walsh S; Finn DP; Dowd E
    Neuroscience; 2011 Feb; 175():251-61. PubMed ID: 21145947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites.
    Heuer A; Smith GA; Lelos MJ; Lane EL; Dunnett SB
    Behav Brain Res; 2012 Mar; 228(1):30-43. PubMed ID: 22146593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra.
    Kitamura Y; Inden M; Minamino H; Abe M; Takata K; Taniguchi T
    Glia; 2010 Nov; 58(14):1686-700. PubMed ID: 20629191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
    Winkler C; Kirik D; Björklund A; Cenci MA
    Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin protects nigrostriatal dopaminergic neurons and reduces glial activation in 6-hydroxydopamine hemiparkinsonian mice model.
    Tripanichkul W; Jaroensuppaperch EO
    Int J Neurosci; 2012 May; 122(5):263-70. PubMed ID: 22176529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism.
    Brown AR; Hu B; Antle MC; Teskey GC
    Exp Neurol; 2009 Nov; 220(1):162-70. PubMed ID: 19703443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration.
    Ghorayeb I; Puschban Z; Fernagut PO; Scherfler C; Rouland R; Wenning GK; Tison F
    Exp Neurol; 2001 Jan; 167(1):133-47. PubMed ID: 11161601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
    Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
    Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
    Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranigral transplantation of solid tissue ventral mesencephalon or striatal grafts induces behavioral recovery in 6-OHDA-lesioned rats.
    Palmer MR; Granholm AC; van Horne CG; Giardina KE; Freund RK; Moorhead JW; Gerhardt GA
    Brain Res; 2001 Jan; 890(1):86-99. PubMed ID: 11164771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Intrastriatal 6-OHDA Lesions on Extrastriatal Brain Structures in the Mouse.
    Becker B; Demirbas M; Johann S; Zendedel A; Beyer C; Clusmann H; Haas SJ; Wree A; Tan SKH; Kipp M
    Mol Neurobiol; 2018 May; 55(5):4240-4252. PubMed ID: 28616718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice.
    Richter F; Hamann M; Richter A
    Brain Res; 2008 Jan; 1188():148-56. PubMed ID: 18035334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Sleeman IJ; Boshoff EL; Duty S
    Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
    Fletcher EJR; Moon LDF; Duty S
    BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel use of combined tyrosine hydroxylase and silver nucleolar staining to determine the effects of a unilateral intrastriatal 6-hydroxydopamine lesion in the substantia nigra: a stereological study.
    Healy-Stoffel M; Ahmad SO; Stanford JA; Levant B
    J Neurosci Methods; 2012 Sep; 210(2):187-94. PubMed ID: 22850559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
    Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
    Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.